English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

The present research article represents the formulation and evaluation of buccoadhessive film of ropinirole hydrochloride.This drug is an oral non-ergoline dopamine agonist with the greater affinity at D3 receptor. This drug having lowmolecular weight (296.84 g/mol), and short biological half-life (4-6 hrs) which necessitates for multiple dosing formaintaining therapeutic effect throughout the day. Moreover, drug is metabolized in liver forming several inactivemetabolites which decrease it oral bioavailability upto 50% making it a suitable candidate for administration of drugthrough buccal mucosa. Buccal films of ropinirole hydrochloride were prepared using various polymers (HPMC, EC,PVA and Carbopol) by solvent casting method using propylene glycol as plasticizer. These films were evaluated forvarious parameter such as appearance, surface texture, weight uniformity, thickness, folding endurance, surface pH, drugcontent and swelling index. All the formulations were subjected to in vitro drug release study which were carried outusing egg membrane as semi permeable membrane.

Development and Evaluation of Buccoadhesive Film of Ropinirole Hydrochloride for the Treatment of Parkinson’s Disease